Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
about
Taxane platinum combination chemotherapy versus single agent platinum for the first line treatment of epithelial ovarian cancerTaxane-platinum combination chemotherapy versus single agent platinum for the first-line treatment of epithelial ovarian cancerShort versus long duration infusions of paclitaxel for any advanced adenocarcinomaNo significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatinOutcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinomaRole of primary surgery in advanced ovarian cancerOvarian cancer standard of care: are there real alternatives?Advanced ovarian cancer: what should be the standard of care?Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentSelective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell linesDocetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerQuality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.Role of cytoreductive surgery in recurrent ovarian cancer.Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapyFour cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data.Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinumTP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.Toxicities of the platinum antineoplastic agents.Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancerPharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerSafety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cellsGene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based MedicineEfficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model.Ovarian cancer (advanced)Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapyMifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Preclinical profile of cabazitaxel.PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.New developments in the treatment of ovarian cancer.Clinical trials and progress with paclitaxel in ovarian cancerPhase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
P2860
Q24188289-E9934517-02CC-47D1-ACC4-839FA2BCA3B1Q24202696-10478A3B-EB63-406A-B8D4-6769A34FCAA0Q24234425-A1ABF3E9-6941-4867-9A35-9980DE52A2F4Q24531843-8035638C-C8A0-4CC1-ADFE-D3C430DF1C2AQ24791107-649A7DF4-7157-4A70-A021-060CE8418E0CQ24803931-163D2B81-E1A5-4C27-9D1E-179027ACD4A1Q26862249-4A9851AD-F344-4D23-BEB2-C9F932620869Q27852053-C1A3A060-70F9-4D01-929A-D997A0521252Q28073057-F4F33DA6-166F-4A24-A52C-B7BAB2210787Q28344057-41F2B60F-FF7D-4423-A49A-68A0567D0875Q28346751-37BF5CD5-2A28-4E87-8B83-35F6D3A7E4F9Q30358112-6185E7A8-399B-4CD8-B0FF-FFFD2FD9D624Q30378801-DB5FCE11-1213-4C04-9158-B741F5D86847Q30434977-71696722-B5B4-49B3-B277-AF5838CB2C6DQ30436714-CF22BEB0-C2D8-4922-AA7B-E9E2B94556F4Q30494709-118B2CE8-DB84-4FD5-B10D-C44A39178F11Q30827244-9BCFBF39-F69A-4609-B978-7FDFE0695407Q30983330-5D6E643B-BACA-4688-97EB-34609CCA5A3FQ33293726-BCD6BBBE-6C47-4B61-81EA-2F1D772EAB24Q33317044-4F616756-D9AD-481E-A30A-9BBEF7581D6CQ33357351-115A6951-ED0C-45B8-9023-C76D9173008AQ33360212-FD5A1230-7B14-4496-8D6D-4E50E335CE6AQ33366785-F5B34CE4-9758-4D43-B131-FBB390307FE8Q33372127-8BECB906-DE43-4B6E-9FF2-8EBDD634FBD0Q33376938-79E94D8A-8E0B-44A9-BFDB-7BC811C31326Q33511042-0BF4377E-48E3-4071-81C4-2AA51C58491FQ33534491-A3E9F806-ECCF-4581-8B9B-E5F0797DBEBDQ33543156-EDE311FD-9AAF-46CA-9AB7-62F5CCD1AA5EQ33572395-45128082-C18D-44BD-9178-A412C153D552Q33813161-CB41175F-9568-449D-9B5B-B4337F8CE635Q33998342-9D6C001E-1B71-4C22-9FAA-ED2828956041Q34010642-6FF51901-2324-41ED-9572-DCDD2CB56D50Q34069349-D6C02ACE-CE21-42FB-A25B-8A5A5F857976Q34122814-5ED83D71-FD0B-44DA-9F3D-92CD538AFB05Q34285363-1AC166C8-078F-4DCD-A6FE-A70EDFD98FB5Q34394251-5FDE704A-4D73-4AB1-A93C-BCD36785779BQ34436731-027AA863-0BD3-4BB6-97C9-C2CB84DB6451Q34481522-3EC17E65-FC18-455C-8864-B86D767A8C95Q34510070-6DA41DFF-5827-4B25-8552-305092CF2A6AQ34552660-FF6254B5-5D44-4C42-9FAC-B5CD08983686
P2860
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Randomized intergroup trial of ...... an cancer: three-year results.
@ast
Randomized intergroup trial of ...... an cancer: three-year results.
@en
Randomized intergroup trial of ...... an cancer: three-year results.
@nl
type
label
Randomized intergroup trial of ...... an cancer: three-year results.
@ast
Randomized intergroup trial of ...... an cancer: three-year results.
@en
Randomized intergroup trial of ...... an cancer: three-year results.
@nl
prefLabel
Randomized intergroup trial of ...... an cancer: three-year results.
@ast
Randomized intergroup trial of ...... an cancer: three-year results.
@en
Randomized intergroup trial of ...... an cancer: three-year results.
@nl
P2093
P356
P1476
Randomized intergroup trial of ...... an cancer: three-year results.
@en
P2093
Andersen JE
Atkinson RJ
Bertelsen K
Grimshaw R
P304
P356
10.1093/JNCI/92.9.699
P407
P577
2000-05-01T00:00:00Z